Experimental drug roscovitine tested in cystic fibrosis patients

NCT ID NCT02649751

Terminated Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tested an experimental drug called roscovitine in 36 adults with cystic fibrosis who have a common genetic mutation and a chronic lung infection. The goal was to check the safety of different doses given in short cycles. The study was terminated early, so its findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Roscovitine (also called Seliciclib)
What this could lead to: If successful, this could point toward a new treatment to control lung infections in people with cystic fibrosis.
What could go wrong: This is an early, small trial that was terminated, so results are limited. The drug may not prove safe or effective, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

CH Lyon Sud

Lyon, 69495, France
CHR - Hôpital Calmette

Lille, 59037, France
CHU Nantes

Nantes, 44093, France
CHU de Bordeaux - Hôpital Haut-Lévêque

Pessac, France, 33604, France
CHU de Nice - Hôpital Pasteur

Nice, France, 06001, France
Centre Hospitalier Bretagne Atlantique

Vannes, France, 56017, France
Centre de Perharidy

Roscoff, 29684, France
Centre de Ressources et de Compétences de la mucoviscidose

Reims, France, 51100, France
Hôpital Arnaud de Villeneuve

Montpellier, 34295, France
Hôpital Cochin

Paris, 75014, France
Hôpital Larrey

Toulouse, 30030, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.